Clinical trials: Nash
Non Alcoholic Fatty Liver Disease
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with…
- Trial name
- NCT02178839
- Testing
- β- glucan, Maltodextrin
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Urmia University of Medical Sciences
NAFLD
Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
BRB-018-001 is a multicenter, adaptive design, randomized, parallel group study to evaluate the safety, tolerability, and PK of repeat IV doses of RYI-018 in subjects with NAFLD.
- Trial name
- NCT03261739
- Testing
- RYI-018
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 84 people
- Sponsor
- Bird Rock Bio, Inc.
NAFLD - Nonalcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis
Curcumin for Pediatric Nonalcoholic Fatty Liver Disease
This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT04109742
- Testing
- phosphatidylcholine-curcumin complex supplement
- Sponsor
- Columbia University
Type 2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease (NAFLD)
Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes
This study is aimed at calculating the incidence of nonalcoholic fatty liver disease (NAFLD), non- alcoholic steatohepatitis (NASH) cirrhosis and advanced fibrosis in patients with type 2 diabetes in China, evaluating the…
- Trial name
- NCT03525769
- Testing
- FibroTouch
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-alcoholic Fatty Liver Disease
Urinary Metabonomics of Two Major Patterns of NAFLD
NAFLD(non-alcoholic fatty liver disease, NAFLD) is a common liver disease with a high morbidity which seriously influence people's health.
- Trial name
- NCT02077283
- Where
- China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- ShuGuang Hospital
Obesity, NAFLD
Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD
The aim of the study is to estimate the effectiveness of two different exercise programs combined with the Mediterranean diet versus diet alone on inflammatory status in subjects aged 18-65 years with obesity (BMI>30) and…
- Trial name
- Obesity_AF (NCT06186869)
- Testing
- Aerobic Exercise and diet intervention, Hiit and diet intervention, Diet
- Where
- Italy
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Non Alcoholic Fatty Liver Disease
Prevention and Reversion of NAFLD in Obese Patients With Metabolic Syndrome by Mediterranean Diet and Physical Activity
This prospective randomized trial evaluates the role of customized dietary and physical activity intervention on the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with obesity and presenting at least three…
- Trial name
- FLIPAN (NCT04442620)
- Testing
- Physical activity and Mediterranean Diet (PA-MD), High meal frequency of Mediterranean Diet (HMF-MD), Control diet (CD)
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- University of the Balearic Islands
Non-Alcoholic Steatohepatitis (NASH), Diabetes Mellitus Type 2 (T2DM)
Efficacy and Tolerability of a Specialized Food Products for Dietary Therapeutic and Preventive Nutrition Based on Ice Cream (Ice Cream With Brazzein, Maltitol and Oligofructose; Ice Cream With Brazzein, Erythritol, Maltitol and Inulin) Compared to Standard (Sundae) Ice Cream
This is a double-blind, randomized, comparative controlled cross-over study of efficacy and tolerability of 2 specialized food products based on ice cream compared to the standard (sundae) ice cream for patients with…
- Trial name
- NCT06724913
- Testing
- specialized food product based on ice cream, specialized food product based on ice cream 2, specialized food product based on ice cream 3
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Federal State Budgetary Scientific Institution
Chronic Hepatitis b, NAFLD
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Chronic hepatitis B (CHB) affects 257million individuals worldwide. In 2017, it caused around 39.7 million cases of cirrhosis and 0.4 million cirrhosis-related deaths in 2017.
- Conditions
- Chronic Hepatitis b, NAFLD, Cirrhosis, Fibrosis, Liver
- Trial name
- NCT05147090
- Testing
- Empagliflozin 10 MG
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong
Metabolic Dysfunction-Associated Fatty Liver Disease
Evaluate the Effect of Synbiotics on MAFLD
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. Available data indicates that probiotics may regulate the gut microbiota, while Vitamin E and omega 3 are safe and effective at…
- Trial name
- MAFLD-RCT (NCT06537882)
- Testing
- G-NiiB synbiotics formula (SLP07)
- Where
- Hong Kong
- Volunteers
- 54 people
- Sponsor
- GenieBiome Limited
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes
Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes.
- Trial name
- NCT07269197
- Testing
- Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
- Where
- Croatia
- Volunteers
- 67 people
- Sponsor
- Josip Juraj Strossmayer University of Osijek
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease
This study will look at physical activity and nutrition in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT03839082
- Testing
- Usual Care then FitBit, FitBit then Usual Care
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy…
- Trial name
- NCT05107336
- Testing
- AZD2693
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04389593
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
NAFLD (Non-Alcoholic Fatty Liver Disease), Resistance Training
The Role of Resistance Training in Non Alcoholic Fatty Liver Disease
The aim of the study is to evaluate the effect of RT on clinical and metabolic parameters in patients with NAFLD.
- Trial name
- NCT01264198
- Testing
- Resistance Training
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
NAFLD, Liver Fibrosis
Different Doses of ZED1227 vs. Placebo in NAFLD
This is a double-blind, randomized, multicenter, placebo-controlled, comparative, exploratory phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will…
- Trial name
- NormaliZED (NCT05305599)
- Testing
- ZED1227
- Where
- Germany
- Volunteers
- 186 people
- Sponsor
- Dr. Falk Pharma GmbH
Metabolic-dysfunction-associated Fatty Liver Disease (MAFLD)
Noninvasive Assessment of Metabolic Associated Fatty Liver Disease (MAFLD) in Chinese Population
Attenuation imaging (ATI) technology independently developed by Canon medical is a non-invasive examination technology for quantitative detection and analysis of liver steatosis.
- Trial name
- NCT04551716
- Where
- China
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
NAFLD, Urinary Lithiasis
The Study of Lithogenesis Processes in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, ranging from pure steatosis to non-alcoholic steatohepatitis and ultimately to liver cirrhosis.
- Trial name
- LINA (NCT06357052)
- Where
- Italy
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- HHTN (NCT06449833)
- Testing
- Henagliflozein and Metformin, Linagliptin and Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Metabolic-associated Fatty Liver Disease (MAFLD)
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease…
- Trial name
- NCT06078722
- Where
- 7 sites in Kazakhstan
- Volunteers
- 264 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.